AES Corp vs Axogen Inc — how do they compare? AES Corp trades at $14.72 (market cap $10.51B), while Axogen Inc trades at $48.35 (market cap $2.59B). The key difference: AES Corp is far larger — about 4.1× Axogen Inc's market cap, and AES Corp pays a 4.78% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AES | AXGN | |
|---|---|---|
Market Cap | $10.51B | $2.59B |
Sector | Utilities | Technology |
52-Week High | $17.28 | $48.48 |
52-Week Low | $12.51 | $14.16 |
Enterprise Value | $40.77B | $2.50B |
Dividend Yield | 4.78% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
AXGN is trading at $46.43, up 4.69% today, with strong technical momentum and bullish moving average signals. The company reported Q2 2026 revenue growth of 23.1% to $69.7 million and raised full-year guidance to at least $279 million. Despite recent earnings misses, analyst sentiment remains overwhelmingly positive with 84% buy ratings and a $54.33 price target.
The stock presents growth potential driven by expanding nerve care platform adoption and reimbursement improvements, but faces risks from persistent net losses (-$15.7M in 2025) and high valuation multiples (P/S 9.5). Near-term performance hinges on Q3 earnings delivery and continued commercial execution amid competitive pressures.
Trailing returns across standard periods
AES is a global power company operating across 14 countries and 4 continents. Its current generation portfolio as of year-end 2021 consists of over 31 gigawatts of generation, with the generation mix composed of renewables (43%), gas (32%), coal (23%), and oil (2%). The company has 3.5 gigawatts of generation under construction. AES has majority ownership and operates six electric utilities distributing power to 2.6 million customers.
Read more on AES →Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →